Zoetis is building on a long-term relationship with Stabilitech, a pioneer in thermostable technologies that preserve the efficacy of medicines and vaccines against high and low temperature extremes.
Zoetis and Stabilitech entered a three-year collaboration which will explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals.
Vaccines and other large biomolecules that could be sterilized, transported and stored at room temperature without significant degradation have the potential to transform animal healthcare – especially in developing countries where access to refrigeration in rural areas is a challenge.
I am delighted to be able to inform you that we have entered into an option and license agreement with GSK to evaluate Stabilitech’s thermal stability platform technology.
As you know, the Stabilitech platform technology enables development of thermally stable vaccines and biopharmaceuticals.
Under the terms of the research collaboration, GSK has the option to take an exclusive license for use in a defined field. We are not able to disclose further terms of the collaboration.
This is the second project we have worked on with GSK and is further technical validation of our technology and a milestone in our commercialization strategy.